Antibe Therapeutics Announces the Appointment of New Board Member and Provides Update on Phase 2 Trial of ATB-346
TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV:ATE, OTCQX:ATBPF), a commercial-stage pharmaceutical growth company, is pleased to announce the appointment of Yung Wu to its Board of Directors.
“We’re delighted by the addition of Yung to our Board of Directors. We see many growth opportunities ahead for Antibe and we will benefit from Yung’s unique insights and perspectives as we work to unlock the full potential of the Company,” said Walt Macnee, Antibe’s Chair of the Board. “We look forward to continuing a long-term growth trajectory that maximizes shareholder value.”
“We’re delighted by the addition of Yung to our Board of Directors. We see many growth opportunities ahead for Antibe and we will benefit from Yung’s unique insights and perspectives as we work to unlock the full potential of the Company,” said Walt Macnee, Antibe’s Chair of the Board. “We look forward to continuing a long-term growth trajectory that maximizes shareholder value.”